experimental melanoma

Summary

Summary: Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.

Top Publications

  1. pmc CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
    Paul A Antony
    Division of Surgery, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:2591-601. 2005
  2. ncbi The Abl interactor proteins localize to sites of actin polymerization at the tips of lamellipodia and filopodia
    T Stradal
    Institute of Molecular Biology, Austrian Academy of Sciences, 5020, Salzburg, Austria
    Curr Biol 11:891-5. 2001
  3. ncbi Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis
    Juan A Recio
    Laboratory of Molecular Biology, National Cancer Institute, Bethesda, Maryland 20892 4264, USA
    Cancer Res 62:6724-30. 2002
  4. pmc CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    Sergio A Quezada
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1935-45. 2006
  5. ncbi Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells
    M Nesbit
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    J Immunol 166:6483-90. 2001
  6. pmc Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
    Willem W Overwijk
    National Cancer Institute NCI, National Institute of Health, Bethesda, MD 20892 1502, USA
    J Exp Med 198:569-80. 2003
  7. ncbi Transfection of macrophage inflammatory protein 1 alpha into B16 F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors
    Hendrik W van Deventer
    Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
    J Immunol 169:1634-9. 2002
  8. ncbi Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma
    H E Wiley
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 93:1638-43. 2001
  9. pmc Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 206:1717-25. 2009
  10. pmc Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis
    Yiwen Li
    ImClone Systems Incorporated, New York, NY 10014, USA
    J Exp Med 195:1575-84. 2002

Detail Information

Publications225 found, 100 shown here

  1. pmc CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
    Paul A Antony
    Division of Surgery, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:2591-601. 2005
    ..These findings reveal that Th cells can help break tolerance to a persisting self-Ag and treat established tumors through an IL-2-dependent mechanism, but requires simultaneous absence of naturally occurring T(reg) cells to be effective...
  2. ncbi The Abl interactor proteins localize to sites of actin polymerization at the tips of lamellipodia and filopodia
    T Stradal
    Institute of Molecular Biology, Austrian Academy of Sciences, 5020, Salzburg, Austria
    Curr Biol 11:891-5. 2001
    ..Our findings are the first to suggest a direct involvement of members of the Abi protein family in the control of actin polymerization in protrusion events, and establish the Abi proteins as potential regulators of motility...
  3. ncbi Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis
    Juan A Recio
    Laboratory of Molecular Biology, National Cancer Institute, Bethesda, Maryland 20892 4264, USA
    Cancer Res 62:6724-30. 2002
    ....
  4. pmc CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    Sergio A Quezada
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1935-45. 2006
    ....
  5. ncbi Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells
    M Nesbit
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    J Immunol 166:6483-90. 2001
    ..This correlates with the degree of monocytic cell infiltration, which results in increased tumor vascularization and TNF-alpha production...
  6. pmc Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
    Willem W Overwijk
    National Cancer Institute NCI, National Institute of Health, Bethesda, MD 20892 1502, USA
    J Exp Med 198:569-80. 2003
    ....
  7. ncbi Transfection of macrophage inflammatory protein 1 alpha into B16 F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors
    Hendrik W van Deventer
    Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
    J Immunol 169:1634-9. 2002
    ..Our findings suggest that MIP-1 alpha is effective in preventing the initiation of metastasis, but not at sustaining an effective antitumor response...
  8. ncbi Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma
    H E Wiley
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 93:1638-43. 2001
    ..CONCLUSION: Expression of a single chemokine receptor gene, CCR7, increased B16 cell metastasis to draining lymph nodes, suggesting that cancer cells may co-opt normal mechanisms of lymph node homing during metastasis...
  9. pmc Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 206:1717-25. 2009
    ....
  10. pmc Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis
    Yiwen Li
    ImClone Systems Incorporated, New York, NY 10014, USA
    J Exp Med 195:1575-84. 2002
    ..Thus, an active immunization strategy that targets an angiogenesis-related antigen on endothelium can inhibit angiogenesis and may be a useful approach for treating angiogenesis-related diseases...
  11. ncbi Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity
    James W Wells
    Medical Research Council and Asthma UK Centre in Allergic Mechanisms of Asthma, King s College London, Guy s Hospital, United Kingdom
    J Immunol 181:3422-31. 2008
    ..This flexible strategy is more effective than existing adjuvants and provides a technological platform for rapid vaccine development...
  12. pmc Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
    R P Sutmuller
    Department of Immunohematology and Blood Transfusion, Tumor Immunology Lab, E3-Q, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
    J Exp Med 194:823-32. 2001
    ..Simultaneous intervention with both regulatory mechanisms is therefore a promising concept for the induction of therapeutic antitumor immunity...
  13. pmc The central role of CD4(+) T cells in the antitumor immune response
    K Hung
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Exp Med 188:2357-68. 1998
    ..Cytokines produced by these CD4(+) T cells activate eosinophils as well as macrophages that produce both superoxide and nitric oxide. Both of these cell types then collaborate within the site of tumor challenge to cause its destruction...
  14. ncbi Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis
    Ralf J Ludwig
    Department of Dermatology, Klinikum der J W Goethe Universitat, Frankfurt am Main, Germany
    Cancer Res 64:2743-50. 2004
    ..cell rolling but also attenuates melanoma metastasis formation in vivo, further supporting the concept that endothelial P-selectin expression may represent an additional target of heparin action in experimental melanoma lung metastasis.
  15. doi Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders
    Lois W Brüggemann
    Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    J Cell Mol Med 12:2622-7. 2008
    ....
  16. doi Cancer stem cells sustaining the growth of mouse melanoma are not rare
    Yong Zhong
    Department of Immunology, Cancer Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, 17 Pan Jia Yuan Nan Li, Chao Yang, Beijing, China
    Cancer Lett 292:17-23. 2010
    ..The result of this study does not seem to support the current view that cancer stem cells (CSCs) responsible for the sustainable growth of tumor are rare...
  17. ncbi Differentially oriented populations of actin filaments generated in lamellipodia collaborate in pushing and pausing at the cell front
    Stefan A Koestler
    Institute of Molecular Biotechnology, Austrian Academy of Sciences, Dr Bohr Gasse 3, 1030, Vienna, Austria
    Nat Cell Biol 10:306-13. 2008
    ....
  18. ncbi Regulation of tyrosinase mRNA in mouse melanoma cells by alpha-melanocyte-stimulating hormone
    D Rungta
    Department of Biochemistry and Molecular Biology, University of Oklahoma, Health Science Center, Oklahoma City, USA
    J Invest Dermatol 107:689-93. 1996
    ....
  19. ncbi Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation
    Uta B Hofmann
    Department of Dermatology, Julius Maximilian s University, Wurzburg, Germany
    Cancer Res 63:8221-5. 2003
    ....
  20. ncbi Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor
    J Kjaergaard
    Center for Surgery Research and Lerner Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Immunol 167:6669-77. 2001
    ..Our study suggests OX-40R mAb to be a reagent of choice to augment T cell adoptive immunotherapy in clinical trials...
  21. ncbi TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells
    Christian H Poehlein
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, Portland, OR 97213, USA
    J Immunol 170:2004-13. 2003
    ..These insights could be used to monitor and potentially tune the immune response to cancer vaccines...
  22. pmc Angiostatic activity of obtustatin as alpha1beta1 integrin inhibitor in experimental melanoma growth
    MEGHAN C BROWN
    Department of Neuroscience, Center for Neurovirology and Cancer Biology, Temple University, School of Medicine, Philadelphia, PA, USA
    Int J Cancer 123:2195-203. 2008
    ..of collagen receptor, alpha1beta1 integrin expressed on the endothelial cells on the development of experimental melanoma and pathological angiogenesis...
  23. pmc Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells
    Claudia Wrzesinski
    National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 117:492-501. 2007
    ..These findings indicate that CD8(+) T cell-mediated tumor responses can be efficiently driven by HSCs in the myeloablative setting and have substantial implications for the design of new antitumor immunotherapies...
  24. ncbi Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
    Shiladitya Sengupta
    Biological Engineering Division, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Nature 436:568-72. 2005
    ..The technology can be extended to additional agents, so as to target multiple signalling pathways or distinct tumour compartments, enabling the model of an 'integrative' approach in cancer therapy...
  25. ncbi Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies
    Anna Katharina Simon
    MRC Human Immunology Unit and Nuffield Department of Medicine, Institute of Molecular Medicine, OX3 9DS, Oxford, United Kingdom
    Cancer Cell 2:315-22. 2002
    ..We show that protected mice recognize melanocyte differentiation self-antigens. Importantly, tumor immunity is mediated by antibodies, as it can be transferred by serum from protected mice...
  26. ncbi CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy
    C A Chambers
    University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Annu Rev Immunol 19:565-94. 2001
    ..This review primarily focuses on the cellular and molecular mechanisms of regulation by CTLA-4 and its manipulation as a strategy for tumor immunotherapy...
  27. doi Imaging of mouse experimental melanoma in vivo and ex vivo by combination of confocal and nonlinear microscopy
    Oleksandr Chernyavskiy
    Department of Biomathematics, Institute of Physiology, Academy of Sciences of the Czech Republic, v v i, Videnska 1083, 14220 Prague 4, Czech Republic
    Microsc Res Tech 72:411-23. 2009
    ..possibilities of the combination of the one- and two-photon excitation microscopy for examination of the experimental melanoma tissue in vivo, in mice under general anesthesia, and ex vivo on freshly harvested specimens...
  28. pmc Coupling and uncoupling of tumor immunity and autoimmunity
    W B Bowne
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Exp Med 190:1717-22. 1999
    ..e., antibody versus CD8(+) T cell. However, both pathways led to tumor immunity and identical phenotypic manifestations of autoimmunity...
  29. ncbi Interleukin 12 gene therapy of MHC-negative murine melanoma metastases
    P Nanni
    Institute for Cancer Research, University of Bologna, Italy
    Cancer Res 58:1225-30. 1998
    ..In conclusion, tumor therapy based on IL-12 gene transduction was effective on a MHC-negative metastatic tumor, suggesting a possible application to MHC-defective human neoplasms...
  30. ncbi Multiple pathways to tumor immunity and concomitant autoimmunity
    Mary Jo Turk
    1Weill Graduate School of Medical Sciences of Cornell University, New York, USA
    Immunol Rev 188:122-35. 2002
    ..Autoimmunity uses similar mechanisms as tumor immunity, but tumor immunity and autoimmunity can uncouple. These studies open up strategies for active immunization against cancer...
  31. ncbi A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen
    Jason S Gold
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 170:5188-94. 2003
    ....
  32. ncbi Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice
    P Dematos
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Surg Oncol 68:79-91. 1998
    ....
  33. ncbi Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration
    Tanja Rothhammer
    University of Regensburg Medical School, Regensburg, Germany
    Cancer Res 65:448-56. 2005
    ....
  34. ncbi Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells
    Farida Djouad
    INSERM U475, Montpellier, France
    Transplantation 82:1060-6. 2006
    ..However, because of their immunosuppressive capacities, we investigated the effect of MSC on the development of syngeneic tumors...
  35. pmc Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice
    Halina Was
    Department of Medical Biotechnology, Faculty of Biotechnology, Jagiellonian University, Gronostajowa 7, 30 387 Krakow, Poland
    Am J Pathol 169:2181-98. 2006
    ....
  36. ncbi The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally
    C J Kirk
    Department of Surgery, University of Michigan Medical Center, Ann Arbor, Michigan 48109-0666, USA
    Cancer Res 61:8794-802. 2001
    ..Similar results were obtained in lymphotoxin alpha-/- mice, which lacked peripheral lymph nodes. Our data demonstrate that effective T-cell priming can occur extranodally and result in measurable antitumor effects in vivo...
  37. ncbi Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization
    Y Kotera
    Department of Surgery, University of Michigan Medical Center, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0666, USA
    Cancer Res 61:8105-9. 2001
    ....
  38. ncbi In vivo antitumor activity of interleukin 21 mediated by natural killer cells
    Gang Wang
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer Res 63:9016-22. 2003
    ..Our study suggests that IL-21 has significant antitumor activity and may have therapeutic potentials as an antitumor agent in the clinic...
  39. doi Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21
    Jacqueline D Shields
    Institute of Bioengineering, Ecole Polytechnique Federale de Lausanne, 1015 Lausanne, Switzerland
    Science 328:749-52. 2010
    ..We suggest that by altering the tumor microenvironment, CCL21-secreting tumors shift the host immune response from immunogenic to tolerogenic, which facilitates tumor progression...
  40. ncbi Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration
    Seagal Teitz-Tennenbaum
    Departments of Surgery, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Cancer Res 63:8466-75. 2003
    ..i.t. DC administration combined with RT induces a potent local and systemic antitumor response in tumor-bearing mice. This novel regimen may be beneficial in the treatment of human cancers...
  41. ncbi Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumor necrosis factor alpha enhancement of experimental metastasis
    H Okahara
    First Department of Surgery, School of Medicine, Juntendo University, Tokyo, Japan
    Cancer Res 54:3233-6. 1994
    ..These results indicate that the interaction between VLA-4 on tumor cells and vascular cell adhesion molecule 1 on activated endothelial cells is critically involved in TNF-alpha enhancement of metastasis...
  42. ncbi Angiogenesis, lymphangiogenesis, and melanoma metastasis
    Michael Streit
    Berlex Biosciences, Richmond, CA 94804, USA
    Oncogene 22:3172-9. 2003
    ..These observations have important implications for prognosis and treatment of human melanomas...
  43. pmc Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells
    Mary Jo Turk
    The Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Exp Med 200:771-82. 2004
    ..These results show that regulatory T cells are the major regulators of concomitant tumor immunity against this weakly immunogenic tumor...
  44. pmc Decreased tumor surveillance in perforin-deficient mice
    M E van den Broek
    Institute of Experimental Immunology, University of Zurich, Switzerland
    J Exp Med 184:1781-90. 1996
    ....
  45. pmc Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression
    S J Orlow
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York 10016, USA
    Proc Natl Acad Sci U S A 92:10152-6. 1995
    ....
  46. pmc NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels
    Satoshi Kashiwagi
    Edwin L Steele Laboratory, Department of Radiation Oncology, and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    J Clin Invest 115:1816-27. 2005
    ..These data indicate that endothelial cell-derived NO induces mural cell recruitment as well as subsequent morphogenesis and stabilization of angiogenic vessels...
  47. ncbi Modulatory effect of killed Propionibacterium acnes and its purified soluble polysaccharide on peritoneal exudate cells from C57Bl/6 mice: major NKT cell recruitment and increased cytotoxicity
    R Z Ananias
    Disciplina de Imunologia, Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Scand J Immunol 65:538-48. 2007
    ..Macrophages induced by both P. acnes and PS have their antitumour effect dependent on NO production...
  48. pmc Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice
    A Thies
    Zentrum für Experimentelle Medizin, Institut für Anatomie II Experimentelle Morphologie, Universitatsklinikum Hamburg Eppendorf, Martinistrasse 52, Hamburg D 20246, Germany
    Br J Cancer 96:609-16. 2007
    ....
  49. ncbi Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor
    Daisuke Umeda
    Laboratory of Food Chemistry, Division of Applied Biological Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, Fukuoka 812 8581, Japan
    J Biol Chem 283:3050-8. 2008
    ..Additionally, we found that eEF1A is up-regulated by EGCG through 67LR. Overall, these findings implicate both eEF1A and MYPT1 in EGCG signaling for cancer prevention through 67LR...
  50. pmc Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice
    Raymond M Schiffelers
    Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht, The Netherlands
    Neoplasia 7:118-27. 2005
    ..In conclusion, the present study shows potent antitumor effects of liposomal formulations of glucocorticoids in a low dose and low-frequency schedule, offering promise for liposomal glucocorticoids as novel antitumor agents...
  51. ncbi Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development
    S M Plum
    EntreMed, Inc, 9640 Medical Center Drive, Rockville, MD 20850, USA
    Vaccine 19:1294-303. 2000
    ..These data suggest that a heparin binding domain peptide of FGF-2, when presented to a host in a liposomal adjuvant formulation, can ultimately lead to inhibition of angiogenesis and tumor growth...
  52. doi Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors
    Andrew R Reynolds
    Tumour Angiogenesis Group, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Nat Med 15:392-400. 2009
    ..The proangiogenic effects of low concentrations of RGD-mimetic integrin inhibitors could compromise their efficacy as anticancer agents and have major implications for the use of RGD-mimetic compounds in humans...
  53. ncbi Murine endothelial cell lines as models of tumor endothelial cells
    Jennifer Walter-Yohrling
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Clin Cancer Res 10:2179-89. 2004
    ..These cells can be used in in vitro angiogenesis assays for evaluating the potential antiangiogenic properties and interspecies cross-reactivity of novel compounds...
  54. ncbi The influence of different microenvironments on melanoma invasiveness and microcirculation patterns: an animal experiment study in the mouse model
    Baocun Sun
    Department of Pathology, Tianjin Cancer Hospital and Institute, Tianjin Medical University, Tianjin 300060, People s Republic of China
    J Cancer Res Clin Oncol 133:979-85. 2007
    ..To investigate the influence of different microenvironments on tumor microcirculation patterns and invasiveness capability...
  55. pmc IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells
    Christopher A Klebanoff
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 101:1969-74. 2004
    ..These results provide several avenues for improving adoptive immunotherapy of cancer in patients...
  56. pmc Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis
    Maria I Harrell
    Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Department of Comparative Medicine, University of Washington, 1100 Fairview Ave N, MS C2 023, P O Box 19024, Seattle, WA 98109, USA
    Am J Pathol 170:774-86. 2007
    ..Lymph node lymphangiogenesis and increased lymph flow through tumor-draining lymph nodes may actively promote metastasis via the lymphatics...
  57. ncbi Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
    Tianhong Wang
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Nat Med 10:48-54. 2004
    ..We propose that tumor Stat-3 activity can mediate immune evasion by blocking both the production and sensing of inflammatory signals by multiple components of the immune system...
  58. ncbi A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model
    Jennifer A McWilliams
    Department of Pharmacology, 3M Pharmaceuticals, St Paul, MN 55144, USA
    J Immunol 177:155-61. 2006
    ..However, consistent with most clinical data, simple generation of higher affinity T cells is insufficient to mediate tumor immunity...
  59. ncbi 7th Jan Waldenström Lecture. The biology of human cancer metastasis
    I J Fidler
    Department of Cell Biology, University of Texas M. D. Anderson Cancer Center, Houston
    Acta Oncol 30:668-75. 1991
    ..These data suggest that systemic physiological signals can be usurped by neoplastic cells. Collectively, the factors that regulate metastasis are the intrinsic properties of metastatic cells and host factors involved in homeostasis...
  60. ncbi Expression of heat-stable antigen on tumor cells provides co-stimulation for tumor-specific T cell proliferation and cytotoxicity in mice
    Y C Wang
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    Eur J Immunol 25:1163-7. 1995
    ..In summary, our study demonstrated that HSA can provide a co-stimulatory signal for the T cell immune response against tumor cells in a murine model...
  61. ncbi Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma
    Baocun Sun
    Department of Pathology, Tianjin Cancer Hospital, Tianjin Medical University, Tianjin 300060, PR China
    Cancer Lett 249:188-97. 2007
    ..Hypoxia can enhance tumor cell invasion and metastasis. The cause and the molecular mechanism are still not clear...
  62. ncbi Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression
    A F Tilkin-Mariame
    INSERM U563 CPTP, Département Innovation thérapeutique et Oncologie Moléculaire, Toulouse, France
    FASEB J 19:1513-5. 2005
    ..These observations indicate that protein geranylgeranylation as well as Rho protein are critical for costimulatory and IFN-gamma-dependent MHC class I molecule expression in melanoma...
  63. pmc Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo
    Yanyan Lou
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 64:6783-90. 2004
    ..Collectively, these findings illuminate a new potential application for DCs in the in vivo stimulation of adoptively transferred T cells and may be a useful approach for the immunotherapy of cancer...
  64. ncbi CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer
    Mark J Smyth
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Australia
    J Immunol 176:1582-7. 2006
    ..Our data illustrate at least one mechanism by which Treg can suppress NK cell antitumor activity and highlight the effectiveness of combining Treg inhibition with subsequent NK cell activation to promote strong innate antitumor immunity...
  65. ncbi Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity
    Xin Yuan Chen
    Institute of Molecular Medicine and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, 22 Hankou Road, Nanjing 210093, China
    Clin Cancer Res 12:5834-40. 2006
    ..Because tumor endothelium is rarely targeted by immunity but is critically important for tumor growth, the immunity against tumor endothelium is to be developed as a novel antitumor strategy...
  66. ncbi Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes
    Kristian M Hargadon
    Department of Microbiology and Carter Immunology Center, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Immunol 177:6081-90. 2006
    ..Thus, activated T cells lacking effector function develop through incomplete differentiation in the lymph nodes of late-stage tumor-bearing mice, rather than through suppression of previously differentiated cells...
  67. ncbi In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity
    Fumiyoshi Okano
    Department of Pathology, Stanford University School of Medicine, Palo Alto, CA 94304, USA
    J Immunol 174:2645-52. 2005
    ..These findings demonstrate that unmodified tumor-associated self Ags can be targeted to DCs in vivo to induce potent systemic antitumor immunity...
  68. pmc Induction of potent antitumor immunity by in situ targeting of intratumoral DCs
    Katsuyoshi Furumoto
    Department of Pathology, Stanford University School of Medicine, Palo Alto, California, USA
    J Clin Invest 113:774-83. 2004
    ....
  69. pmc High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction
    Andrew G Brandmaier
    Department of Surgery, Indiana University School of Medicine, and the Walther Oncology Center, Indianapolis, IN 46202, USA
    J Immunother 32:677-88. 2009
    ..These findings suggest that high-avidity CD4+ T cells can overcome endogenous conditions and mediate their antitumor effects exclusively through the elicitation of CD8+ T cell immunity...
  70. pmc A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase
    K Tsukamoto
    Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    EMBO J 11:519-26. 1992
    ..We now report that TRP-2 (tyrosinase related protein-2), which maps to and is mutated at the slaty locus in mice, encodes a protein with DOPAchrome tautomerase activity...
  71. ncbi Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
    J M Kaplan
    Genzyme Corporation, Genzyme Molecular Oncology, Framingham, MA 01701, USA
    J Immunol 163:699-707. 1999
    ..Taken together, these results support the concept of cancer immunotherapy using DCs transduced with Ad vectors encoding tumor-associated Ags...
  72. doi Inhibition of alpha(4) integrin mediated adhesion was involved in the reduction of B16-F10 melanoma cells lung colonization in C57BL/6 mice treated with gambogic acid
    Jie Zhao
    Jiangsu Key Laboratory of Carcinogenesis and Intervention China Pharmaceutical University, Nanjing, PR China
    Eur J Pharmacol 589:127-31. 2008
    ..Thus we concluded for the first time that gambogic acid could inhibit the adhesion and migration of B16-F10 cells in vitro and in vivo, in which down-regulation of alpha(4) integrin expression was involved...
  73. ncbi An attempt to isolate genes responsible for spontaneous and experimental metastasis in the mouse model
    A Ito
    Department of Pathology, Osaka University Medical School, Suita, Japan
    Histol Histopathol 17:951-9. 2002
    ..Moreover, similar roles were expected for the genes in the process by which human melanoma cells metastasize...
  74. ncbi Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth
    K Takeda
    Department of Immunology, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo ku, Tokyo, Japan
    Cell Immunol 214:194-200. 2001
    ..These results suggested a substantial role of TRAIL as the effector molecule that eliminates subcutaneously developing TRAIL-sensitive tumors...
  75. pmc The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma
    H Haghnegahdar
    Department of Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Leukoc Biol 67:53-62. 2000
    ..These data suggest that continuous expression of MGSA/GRO proteins may facilitate tumor growth by stimulating the growth of microvessels into the tumor (paracrine) and by affecting melanocyte growth (autocrine)...
  76. pmc B16 as a mouse model for human melanoma
    W W Overwijk
    National Cancer Institute, NIH, Bethesda, Maryland, USA
    Curr Protoc Immunol . 2001
    ..Additional sections, including growing B16 melanoma, enumerating pulmonary metastases, and use of recombinant viruses for vaccination, are discussed together with safety concerns...
  77. ncbi Engagement of the OX-40 receptor in vivo enhances antitumor immunity
    A D Weinberg
    Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR 97213, USA
    J Immunol 164:2160-9. 2000
    ....
  78. ncbi Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma
    M Bellone
    Laboratory of Tumor Immunology, Cancer Immunotherapy and Gene Therapy Program, H San Raffaele Scientific Institute, Milan, Italy
    J Immunol 165:2651-6. 2000
    ..Our results strongly emphasize the relevance of the tumor Ag in the definition of immunotherapeutic strategies for cancer, and support the use of peptide-pulsed DC as cancer vaccine in humans...
  79. pmc Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells
    Michael Y Gerner
    Center for Immunology, University of Minnesota, Minneapolis, MN 55455, USA
    J Immunol 182:2726-37. 2009
    ..These results show that TIDC are functionally distinct from normal interstitial DC, thus indicating that neoplastic tissues can evade effector CD4 T cells through modification of DC competence...
  80. ncbi Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene: results from a murine tumour model
    C Wack
    Department of Toxicology, , Versbacher Strasse 9, , Germany
    Melanoma Res 11:247-53. 2001
    ..In conclusion, we have established a model system that seems to be appropriate for both the optimization of this therapeutic regimen and the characterization of effector mechanisms...
  81. ncbi Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells
    B Seliger
    Johannes Gutenberg Universitat, III Medizinische Klinik, Mainz, Germany
    Cancer Res 61:1095-9. 2001
    ....
  82. ncbi Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy
    H Winter
    Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, OR 97213, USA
    J Immunol 166:7370-80. 2001
    ..These results indicate that in this adoptive immunotherapy model, neither a direct effect on the tumor nor an indirect effect of IFN-gamma through activation of myeloid or lymphoid cells is critical for therapeutic efficacy...
  83. pmc Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue
    Manuela Banciu
    Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Neoplasia 10:108-17. 2008
    ..One of the major inhibitory actions of LCL-PLP on tumor growth is the reduction of the TAM-mediated production of pro-angiogenic factors, whereas production of anti-angiogenic factors by these cells is hardly affected...
  84. pmc Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice
    Chengwen Liu
    Department of Melanoma Medical Oncology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 118:1165-75. 2008
    ..Our data thus demonstrated that activated pDCs are capable of initiating effective and systemic antitumor immunity through the orchestration of an immune cascade involving the sequential activation of NK cells, cDCs, and CD8(+) T cells...
  85. ncbi Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma
    Romina S Goldszmid
    Instituto Leloir, Instituto de Investigaciones Bioquímicas Buenos Aires, Argentina
    J Immunol 171:5940-7. 2003
    ..Therefore, DCs loaded with cells undergoing apoptotic death can prime melanoma-specific helper and CTLs and provide long term protection against a poorly immunogenic tumor in mice...
  86. ncbi Effect of blocking TNF on IL-6 levels and metastasis in a B16-BL6 melanoma/mouse model
    S Cubillos
    Laboratorio de Fisiopatologia, Instituto Venezolano de Investigaciones Cientificas (IVIC, Caracas, Venezuela
    Anticancer Res 17:2207-11. 1997
    ..The results suggest that the reduction in the number of metastases may be related to the effect of blocking TNF activity...
  87. ncbi Stealth and non-stealth nanocapsules containing camptothecin: in-vitro and in-vivo activity on B16-F10 melanoma
    Gecioni Loch-Neckel
    Laboratório de Farmacotécnica, Departamento de Ciencias Farmaceuticas, Universidade Federal de Santa Catarina, Brazil
    J Pharm Pharmacol 59:1359-64. 2007
    ..This assumption was supported by the in-vitro study, in which both PLA and 49 kDa PLA-PEG nanocapsules containing CPT were more cytotoxic than the free drug against B16-F10 melanoma cells...
  88. ncbi IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma
    Hak Ling Ma
    Wyeth Research, Cambridge, MA 02140, USA
    J Immunol 171:608-15. 2003
    ..We conclude that IL-21 immunotherapy warrants clinical evaluation as a potential treatment for cancer...
  89. pmc Subcellular localization of myosin-V in the B16 melanoma cells, a wild-type cell line for the dilute gene
    A A Nascimento
    Department of Morphology, Faculdade de Medicina de Ribeirao Preto Universidade de Sao Paulo, Brazil
    Mol Biol Cell 8:1971-88. 1997
    ....
  90. ncbi Recombined CC chemokine ligand 2 into B16 cells induces production of Th2-dominant [correction of dominanted] cytokines and inhibits melanoma metastasis
    Kaimeng Hu
    Research Center of Developmental Biology and Department of Histology and Embryology, Second Military Medical University, Shanghai 200433, PR China
    Immunol Lett 113:19-28. 2007
    ....
  91. ncbi Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells
    Mohammed Amarzguioui
    The Biotechnology Centre of Oslo, Norway
    Clin Cancer Res 12:4055-61. 2006
    ..The purposes of this work are to establish a noncytotoxic in vivo model for investigation of tissue factor function and provide preclinical assessment of the therapeutic potential of tissue factor siRNA for prevention of metastasis...
  92. ncbi IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb
    Daisuke Kamimura
    Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology, Yokohama, Kanagawa, Japan
    J Immunol 177:306-14. 2006
    ..These results demonstrated IL-2-enhancing effects of the anti-IL-2 mAb in vivo and suggest that combining a neutralizing anti-IL-2 Ab with IL-2 gene delivery might be used effectively to enhance IL-2 functions in clinical applications...
  93. pmc Inhibition by tyroserleutide (YSL) on the invasion and adhesion of the mouse melanoma cell
    Zhi Yao
    The College of Pharmaceuticals and Biotechnology, Tianjin University, Tianjin, China
    Mol Med 13:14-21. 2007
    ..31%. By analyses with Western blot and real-time RT-PCR, we found that YSL markedly inhibited the expression of ICAM-1 in B16-F10 cells. These data suggest that YSL inhibits the growth, invasion, and adhesion of B16-F10 cells...
  94. doi Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis
    Amnon Hoffman
    Department of Pharmaceutics, The Hebrew University of Jerusalem, Jerusalem, Israel
    J Med Chem 51:1406-14. 2008
    ..Finally, 84% of the intravenously administered cis-ACCP to rats was excreted intact in the urine...
  95. ncbi Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes
    Siguo Hao
    Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan S7N 4H4, Canada
    Cell Mol Immunol 3:205-11. 2006
    ..Therefore, DC-derived EXO may represent a more effective EXO-based vaccine in induction of antitumor immunity...
  96. ncbi Antitumor activity of IFN-lambda in murine tumor models
    Atsuko Sato
    Division of Organ Replacement Research, Center for Molecular Medicine, Jichi Medical School, Shimotsuke, Tochigi, Japan
    J Immunol 176:7686-94. 2006
    ..These findings suggested that local delivery of IFN-lambda might prove a useful adjunctive strategy in the clinical treatment of human malignancies...
  97. ncbi Antiangiogenic and antitumor activities of IL-27
    Motomu Shimizu
    Medical R and D Center, Tokyo Metropolitan Institute of Medical Science, Tokyo Metropolitan Organization for Medical Research, Honkomagome, Bunkyo ku, Japan
    J Immunol 176:7317-24. 2006
    ..These results suggest that IL-27 possesses potent antiangiogenic activity, which plays an important role in its antitumor and antimetastatic activities...
  98. ncbi GM-CSF-surface-modified B16.F10 melanoma cell vaccine
    Jimin Gao
    Institute of Molecular Immunology, College of Biotechnology, Southern Medical University, 1838 Guangzhou Dadao Bei, Guangzhou, Guangdong 510515, China
    Vaccine 24:5265-8. 2006
    ..F10 whole tumor cell vaccine could induce strong and long-lasting systemic protection against the wild-type tumor challenge. Therefore, the platform may represent a fast, efficient and safe approach for the whole tumor cell vaccination...
  99. ncbi Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase: quantitative analysis with firefly luciferase-expressing melanoma cells
    Kenji Hyoudou
    Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
    Clin Cancer Res 10:7685-91. 2004
    ..On the basis of the results obtained, PEG-catalase was repetitively administered to completely suppress the growth of tumor cells...
  100. ncbi Inhibition of tumor growth in mice by endostatin derived from abdominal transplanted encapsulated cells
    Huaining Teng
    Institute of Biochemistry and Cell Biology, Model Organism Research Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
    Acta Biochim Biophys Sin (Shanghai) 39:278-84. 2007
    ..These results widen the clinical application of the microencapsulated cell endostatin delivery system in cancer treatment...
  101. ncbi Effect of amentoflavone on the inhibition of pulmonary metastasis induced by B16F-10 melanoma cells in C57BL/6 mice
    C Guruvayoorappan
    Amala Cancer Research Centre, Amala Nagar, Thrissur, Kerala, India
    Integr Cancer Ther 6:185-97. 2007
    ....

Research Grants118 found, 100 shown here

  1. SPORE in Skin Cancer
    Meenhard Herlyn; Fiscal Year: 2007
    ..CTCL is addressed in one Project and one Pilot Study, and SCC in one Pilot Study. This endeavor represents the synergistic integration of well-established individual research programs towards our collective goals. ..
  2. Inhibition of Angiogenesis by Thrombospondin-1
    JOHN LAWLER; Fiscal Year: 2002
    ..members), (3) evaluate the ability of TSP-1 domains to induce endothelial and tumor cell apoptosis in experimental melanoma and pancreatic cancer, and (4) investigate whether or not the TSP-1-deficient and TSP-1, CD36 double ..
  3. Inhibition of Melanoma metastasis by Eristostatin
    Mary Ann McLane; Fiscal Year: 2001
    ..The specific goal proposed here is to investigate hoe eristostatin inhibits experimental melanoma metastasis by pursuing three specific aims: i) Create a panel of eristostatin mutations designed to alter ..
  4. GANGLIOSIDE MEDIATED IMMUNOTHERAPY OF HUMAN CANCER
    REIKO IRIE; Fiscal Year: 1993
    ..the renewal application we will first evaluate the anti-tumor effect of the GM3 anti-id vaccine using an experimental melanoma model...
  5. LEVODOPA AND DOPAMINE AS THERAPY FOR HUMAN MELANOMA
    Michael Wick; Fiscal Year: 1980
    Levodopa and dopamine have been shown in preclinical studies to be effective antitumor agents against experimental melanoma. A characteristic biochemical effect of these drugs upon tumor cells has been a rapid and complete inhibition of ..
  6. Targeting the MAP and PI3 Kinase Pathways in Melanoma
    MEENHARD FOLKENS HERLYN; Fiscal Year: 2011
    ..unique in vitro and in vivo models of human metastatic melanoma that provide an optimal environment for experimental melanoma therapy. Specifically, we propose to: 1...
  7. MELANOTIC EXPRESSION IN CARCINOGEN-INDUCED MELANOMAS
    J Whittaker; Fiscal Year: 1980
    ..between melanotic expression, growth activities, and various aspects of tumorigenesis and malignancy in experimental melanoma tumors of the Syrian hamster...
  8. Tumor Suppressors in Spontaneous and UV-Induced Melanoma Models
    Rodney Nairn; Fiscal Year: 1999
    ..by the hybridization of different Xiphophorus species will be exploited to develop and analyze several new experimental melanoma models, with the goal of identifying genetic determinants of spontaneous and HIV-induced tumorigenesis...
  9. Electrically Mediated Delivery of Immunostimulatory DNA to Experimental Melanomas
    Loree Heller; Fiscal Year: 2005
    ....
  10. Electrically Mediated Delivery of Immunostimulatory DNA to Experimental Melanomas
    Loree Heller; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  11. TARGETED DRUG AND DYE DELIVERY TO THE RETINA
    Ran Zeimer; Fiscal Year: 1993
    ..The extravascular delivery of drugs will be optimized and its application will be tested by treating experimental melanoma with chemotherapeutic agents...
  12. TARGETED DRUG AND DYE DELIVERY TO THE RETINA
    Ran Zeimer; Fiscal Year: 1991
    ..The extravascular delivery of drugs will be optimized and its application will be tested by treating experimental melanoma with chemotherapeutic agents...
  13. TUMOR SUPPRESSOR GENES IN HERITABLE MELANOMA MODELS
    Rodney Nairn; Fiscal Year: 2007
    ..of melanoma formation in Xiphophorus, thereby providing greater scope for exploitation of this unique experimental melanoma model...
  14. TUMOR SUPPRESSOR GENES IN HERITABLE MELANOMA MODELS
    Rodney Nairn; Fiscal Year: 2003
    ..of melanoma formation in Xiphophorus, thereby providing greater scope for exploitation of this unique experimental melanoma model...
  15. TUMOR SUPPRESSOR GENES IN HERITABLE MELANOMA MODELS
    Rodney Nairn; Fiscal Year: 2004
    ..of melanoma formation in Xiphophorus, thereby providing greater scope for exploitation of this unique experimental melanoma model...
  16. TUMOR SUPPRESSOR GENES IN HERITABLE MELANOMA MODELS
    Rodney Nairn; Fiscal Year: 2005
    ..of melanoma formation in Xiphophorus, thereby providing greater scope for exploitation of this unique experimental melanoma model...
  17. TUMOR SUPPRESSOR GENES IN HERITABLE MELANOMA MODELS
    Rodney Nairn; Fiscal Year: 2006
    ..of melanoma formation in Xiphophorus, thereby providing greater scope for exploitation of this unique experimental melanoma model...
  18. TLR-mediated DC activation and immune reconstitution
    Hong Ming Hu; Fiscal Year: 2006
    ..cells, will be activated by Toll-like receptor triggering and then used to vaccinate mice bearing either experimental melanoma or spontaneous mammary carcinoma metastases...
  19. TLR-mediated DC activation and immune reconstitution
    Hong Ming Hu; Fiscal Year: 2007
    ..cells, will be activated by Toll-like receptor triggering and then used to vaccinate mice bearing either experimental melanoma or spontaneous mammary carcinoma metastases...
  20. TLR-mediated DC activation and immune reconstitution
    Hong Ming Hu; Fiscal Year: 2005
    ..cells, will be activated by Toll-like receptor triggering and then used to vaccinate mice bearing either experimental melanoma or spontaneous mammary carcinoma metastases...
  21. TLR-mediated DC activation and immune reconstitution
    Hong Ming Hu; Fiscal Year: 2004
    ..cells, will be activated by Toll-like receptor triggering and then used to vaccinate mice bearing either experimental melanoma or spontaneous mammary carcinoma metastases...
  22. Dendritic cell mediated resistance to B16 melanoma
    Ralph Steinman; Fiscal Year: 2000
    ..abstract_text> ..
  23. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2006
    ..This project will examine bioeffects in cells and tissues and show how to safely use ultrasound contrast agents in diagnostic imaging. ..
  24. ULTRASOUND ENHANCEMENT OF CANCER GENE THERAPY
    Douglas Miller; Fiscal Year: 2002
    ..This research will provide a bridge from the basic research breakthrough to specific therapeutic applications and urgently needed clinical research programs utilizing this novel technology. ..
  25. Migration of Mature and Immature Dendritic Cells
    HENDRIK VAN DEVENTER; Fiscal Year: 2006
    ..All have extensive experience in developing the careers o f young scientists. This work has the support of the Lineberger Comprehensive Cancer Center which has made accessible its core facilities. ..
  26. ULTRASOUND ENHANCEMENT OF CANCER GENE THERAPY
    Douglas Miller; Fiscal Year: 2003
    ..This research will provide a bridge from the basic research breakthrough to specific therapeutic applications and urgently needed clinical research programs utilizing this novel technology. ..
  27. Immunochaperone-based gene therapy targeting prostate cancer
    Xiang yang Wang; Fiscal Year: 2007
    ..The proposed research could lead to the design of a clinical trial for patients with prostate cancer in the very near future. [unreadable] [unreadable] [unreadable]..
  28. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2009
    ..This project will examine bioeffects in cells and tissues and show how to safely use ultrasound contrast agents in diagnostic imaging. ..
  29. Scavenger Receptor-A and Immune Regulation
    Xiang yang Wang; Fiscal Year: 2008
    ..Further, successful testing of SR-A-silenced dendritic cells as a vaccine to break tolerance against tumor- associated self-antigens will provide a novel immunotherapeutic approach targeting the inhibitory innate receptor. ..
  30. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 1999
    ..The quantitative dosimetric information resulting from this research is urgently needed for risk assessment and guidance of sonographers, and for developing the full therapeutic potential of medical ultrasound. ..
  31. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2008
    ..This project will examine bioeffects in cells and tissues and show how to safely use ultrasound contrast agents in diagnostic imaging. ..
  32. ULTRASOUND ENHANCEMENT OF CANCER GENE THERAPY
    Douglas Miller; Fiscal Year: 2001
    ..This research will provide a bridge from the basic research breakthrough to specific therapeutic applications and urgently needed clinical research programs utilizing this novel technology. ..
  33. ULTRASOUND ENHANCEMENT OF CANCER GENE THERAPY
    Douglas Miller; Fiscal Year: 2000
    ..This research will provide a bridge from the basic research breakthrough to specific therapeutic applications and urgently needed clinical research programs utilizing this novel technology. ..
  34. Scavenger Receptor-A and Immune Regulation
    Xiang yang Wang; Fiscal Year: 2007
    ..Further, successful testing of SR-A-silenced dendritic cells as a vaccine to break tolerance against tumor- associated self-antigens will provide a novel immunotherapeutic approach targeting the inhibitory innate receptor. ..
  35. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2001
    ..abstract_text> ..
  36. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2007
    ..This project will examine bioeffects in cells and tissues and show how to safely use ultrasound contrast agents in diagnostic imaging. ..
  37. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2000
    ..The quantitative dosimetric information resulting from this research is urgently needed for risk assessment and guidance of sonographers, and for developing the full therapeutic potential of medical ultrasound. ..
  38. CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
    Robert M Prins; Fiscal Year: 2010
    ..Thus, this is a mechanistic and translational project that is directly related to our long-term objectives stated above and to the mission of promoting public health. ..
  39. Subharmonic Microbubble Signals for Pressure Estimation
    Flemming Forsberg; Fiscal Year: 2007
    ..This will allow potentially life-threatening diseases, such as increased pressure in the liver, to be diagnosed early. [unreadable] [unreadable] [unreadable]..
  40. A tyrosinase-targeted drug design for the treatment of melanoma
    Majid Moridani; Fiscal Year: 2007
    ..In this work we will be developing novel phenol based drugs for treatment of melanoma. [unreadable] [unreadable] [unreadable]..
  41. Contrast-Enhanced Ultrasound Detection of Angiogenesis
    Flemming Forsberg; Fiscal Year: 2004
    ..If successful, this project will permit non-invasive ultrasound evaluations of anti-angiogenic tumor therapies in animals as well as humans. ..
  42. Immune targeting of melanoma-associated antigens in glioma
    Robert Prins; Fiscal Year: 2007
    ..World renowned scientists and technology in many disciplines will serve to enhance the ability of Dr. Prins to accomplish the goals set forth in this application. ..
  43. Subharmonic Microbubble Signals for Pressure Estimation
    Flemming Forsberg; Fiscal Year: 2008
    ..This will allow potentially life-threatening diseases, such as increased pressure in the liver, to be diagnosed early. [unreadable] [unreadable] [unreadable]..
  44. CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
    Robert Prins; Fiscal Year: 2007
    ..Thus, this is a mechanistic and translational project that is directly related to our long-term objectives stated above and to the mission of promoting public health. [unreadable] [unreadable] [unreadable] [unreadable]..
  45. CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
    Robert Prins; Fiscal Year: 2009
    ..Thus, this is a mechanistic and translational project that is directly related to our long-term objectives stated above and to the mission of promoting public health. ..
  46. Immune targeting of melanoma-associated antigens in glioma
    Robert Prins; Fiscal Year: 2008
    ..World renowned scientists and technology in many disciplines will serve to enhance the ability of Dr. Prins to accomplish the goals set forth in this application. ..
  47. CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
    Robert Prins; Fiscal Year: 2008
    ..Thus, this is a mechanistic and translational project that is directly related to our long-term objectives stated above and to the mission of promoting public health. ..
  48. Quantitative Subharmonic Breast Imaging
    Flemming Forsberg; Fiscal Year: 2010
    ....
  49. Development of an Adenoviral Vector with Chimeric Fiber for Malignant Glioma
    MACIEJ LESNIAK; Fiscal Year: 2008
    ....
  50. SYNTHESIS AND EVALUATION OF NOVEL PHOSPHORAMIDATES
    RICHARD BORCH; Fiscal Year: 1999
    ..The ultimate goal is to exploit the unique properties of phosphoramidate chemistry to develop new drugs with reduced host toxicity and increased efficacy against resistant poorly responsive tumors. ..
  51. DNA-based Vaccine for Treatment of Oral Carcinoma
    Edward Cohen; Fiscal Year: 2006
    ..It is expected that development of an effective vaccine to be used alone or in combination with conventional therapy will expand the future therapeutic options available for patients with oral cancer. ..
  52. Functional analysis of Tgfbm3 locus in vascular development and disease
    Rosemary J Akhurst; Fiscal Year: 2010
    ..assessment of disease risk in ailments known to have a TGFB1 associationc) Will provide targets for prophylactic drug development of such diseases d) May provide predictive markers for response to anti-TGFb drug therapies ..
  53. Control of Eye Melanoma Metastasis
    Hans Grossniklaus; Fiscal Year: 2002
    ..Both the IFN and angiostatin will prevent the progression of micrometastases into metastases by anti-angiogenesis. Angiostatin will prevent metastases by an anti-melanoma invasion effect. ..
  54. Anti-angiogenic Tetrathiomolybdate +XRT in NSCLC-Phase 1
    Mohamed Khan; Fiscal Year: 2004
    ..Chest CT and Chest x-ray will be taken to record tumor response, and to compare with 99mTc-MIBI scans. ..
  55. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    Craig Slingluff; Fiscal Year: 2009
    ....
  56. Human Melanoma - Etiology, Progression and Therapy
    Meenhard Herlyn; Fiscal Year: 2008
    ..The biological models developed in projects 1 and 3 will be utilized to select, verify and validate new targets for a growing pipeline of novel strategies for melanoma diagnosis, prognosis, prevention and therapy. ..
  57. Molecular mechanisms of choroidal neovascularization and vascular homeostasis
    ALEXANDER GEORG MARNEROS; Fiscal Year: 2010
    ..These findings are likely to reveal novel molecular targets for the treatment of neovascular age-related macular degeneration. ..
  58. CELL/CELL COMMUNICATION DURING MELANOMA PROGRESSION
    Meenhard Herlyn; Fiscal Year: 2000
    ..This proposal addresses the biological significance of inter-cellular signaling during distinct steps of melanoma tumor progression. ..
  59. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre Triozzi; Fiscal Year: 2007
    ....
  60. EXPERIMENTAL TRANSFORMATION OF HUMAN MELANOCYTES IN VIVO
    Meenhard Herlyn; Fiscal Year: 2008
    ..Our unique model allows a systematic dissection of the biological and molecular events leading to human melanoma formation. ..
  61. EXPERIMENTAL TRANSFORMATION OF HUMAN MELANOCYTES IN VIVO
    Meenhard Herlyn; Fiscal Year: 2000
    ..Our unique in vitro/in vivo models are suitable to investigate etiology, early detection, and prevention of human melanoma. ..
  62. ANTITUMOR IMMUNITY INDUCED BY FUSION CELLS VACCINATION
    Jianlin Gong; Fiscal Year: 2000
    ..3). To assess the effectiveness of fusion cell vaccines in the prevention and treatment of spontaneous breast carcinoma in transgenic mice. ..
  63. METASTASIS--BIOLOGICAL PHENOTYPE AND MODELS FOR THERAPY
    Meenhard Herlyn; Fiscal Year: 2000
    ....
  64. METASTASIS--BIOLOGICAL PHENOTYPE AND MODELS FOR THERAPY
    Meenhard Herlyn; Fiscal Year: 1999
    ....
  65. Applying nanosecond pulse electric fields to treat skin cancer
    RICHARD LEE NUCCITELLI; Fiscal Year: 2010
    ..This promises to become a scar-free therapy that could replace surgery and improve the quality of life for hundreds of thousands of dermatology patients treated for skin cancer each year. ..
  66. EXPERIMENTAL TRANSFORMATION OF HUMAN MELANOCYTES IN VIVO
    Meenhard Herlyn; Fiscal Year: 1999
    ..Our unique in vitro/in vivo models are suitable to investigate etiology, early detection, and prevention of human melanoma. ..
  67. Cell-Cell Communication During Melanoma Development
    Meenhard Herlyn; Fiscal Year: 2009
    ..These studies will demonstrate how dysregulation of homeostasis results in tumor formation and targeting subpopulations of malignant cells leads to successful therapy. ..
  68. Development of an electrical diagnostic for melanoma
    Richard Nuccitelli; Fiscal Year: 2008
    ..If the handheld BFI is able to reliably detect malignant skin lesions, it will improve the quality of life for tens of thousands of dermatology patients in the United States alone. [unreadable] [unreadable] [unreadable]..
  69. CELL/CELL COMMUNICATION DURING MELANOMA PROGRESSION
    Meenhard Herlyn; Fiscal Year: 1999
    ..This proposal addresses the biological significance of inter-cellular signaling during distinct steps of melanoma tumor progression. ..
  70. Molecular mechanisms of choroidal neovascularization and vascular homeostasis
    Alexander Marneros; Fiscal Year: 2008
    ..These findings are likely to reveal novel molecular targets for the treatment of neovascular age-related macular degeneration. ..
  71. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre Triozzi; Fiscal Year: 2008
    ....
  72. Uveal Melanoma Micrometastasis
    Pierre L Triozzi; Fiscal Year: 2010
    ..Micrometastases, microscopic deposits of tumor that have spread via the bloodstream, are present in many patients with uveal melanoma at diagnosis. This project will test new methods of identifying and inhibiting these deposits. ..
  73. Applying nanosecond pulse electric fields to treat skin cancer
    Richard Nuccitelli; Fiscal Year: 2009
    ..This promises to become a scar-free therapy that could replace surgery and improve the quality of life for hundreds of thousands of dermatology patients treated for skin cancer each year. ..
  74. The Etiology of UV-Induced Melanoma
    David Mitchell; Fiscal Year: 2007
    ..From these studies we hope to define the effective solar wavelength boundaries of melanoma, identify the class of DNA damage critical to CMM and elucidate the role of DNA repair in tumor suppression. ..
  75. Biology of Melanoma Matastasis
    Meenhard Herlyn; Fiscal Year: 2003
    ..These studies should lead to a better understanding of the tumor-specific signatures in pathways associated with invasion and metastasis. ..
  76. CELL CELL COMMUNICATION DURING MELANOMA DEVELOPMENT
    Meenhard Herlyn; Fiscal Year: 2003
    ..As additional signaling pathways are being defined, therapeutic strategies that would mimic the regulatory control of keratinocytes over E-cadherin-expressing melanoma cell will be developed as a long-term objective. ..
  77. ANTITUMOR IMMUNITY INDUCED BY FUSION CELLS VACCINATION
    Jianlin Gong; Fiscal Year: 2003
    ..3). To assess the effectiveness of fusion cell vaccines in the prevention and treatment of spontaneous breast carcinoma in transgenic mice. ..
  78. EXPERIMENTAL TRANSFORMATION OF HUMAN MELANOCYTES IN VIVO
    Meenhard Herlyn; Fiscal Year: 2005
    ..Our unique model allows a systematic dissection of the biological and molecular events leading to human melanoma formation. ..
  79. EXPERIMENTAL TRANSFORMATION OF HUMAN MELANOCYTES IN VIVO
    Meenhard Herlyn; Fiscal Year: 2004
    ..Our unique model allows a systematic dissection of the biological and molecular events leading to human melanoma formation. ..
  80. EXPERIMENTAL TRANSFORMATION OF HUMAN MELANOCYTES IN VIVO
    Meenhard Herlyn; Fiscal Year: 2002
    ..Our unique in vitro/in vivo models are suitable to investigate etiology, early detection, and prevention of human melanoma. ..
  81. Cell-Cell Communication During Melanoma Development
    Meenhard Herlyn; Fiscal Year: 2006
    ..These studies will demonstrate how dysregulation of homeostasis results in tumor formation and targeting subpopulations of malignant cells leads to successful therapy. [unreadable] [unreadable] [unreadable]..
  82. The Etiology of UV-Induced Melanoma
    David Mitchell; Fiscal Year: 2006
    ..From these studies we hope to define the effective solar wavelength boundaries of melanoma, identify the class of DNA damage critical to CMM and elucidate the role of DNA repair in tumor suppression. ..
  83. EXPERIMENTAL TRANSFORMATION OF HUMAN MELANOCYTES IN VIVO
    Meenhard Herlyn; Fiscal Year: 2003
    ..Our unique in vitro/in vivo models are suitable to investigate etiology, early detection, and prevention of human melanoma. ..
  84. CELL CELL COMMUNICATION DURING MELANOMA DEVELOPMENT
    Meenhard Herlyn; Fiscal Year: 2004
    ..As additional signaling pathways are being defined, therapeutic strategies that would mimic the regulatory control of keratinocytes over E-cadherin-expressing melanoma cell will be developed as a long-term objective. ..
  85. Biology of Melanoma Matastasis
    Meenhard Herlyn; Fiscal Year: 2004
    ..These studies should lead to a better understanding of the tumor-specific signatures in pathways associated with invasion and metastasis. ..
  86. CELL CELL COMMUNICATION DURING MELANOMA DEVELOPMENT
    Meenhard Herlyn; Fiscal Year: 2002
    ..As additional signaling pathways are being defined, therapeutic strategies that would mimic the regulatory control of keratinocytes over E-cadherin-expressing melanoma cell will be developed as a long-term objective. ..